An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo

Neoplasia

Volumn 12, Issue 10, 2010, Pages 778-788

  Rabbani, Shafaat A ^a   Ateeq, Bushra ^a   Arakelian, Ani ^a   Valentino, Maria Luisa ^a   Shaw, David E ^b,c   Dauffenbach, Lisa M ^d   Kerfoot, Christopher A ^d   Mazar, Andrew P ^e  

^a MCGILL UNIVERSITY   (Canada)

^b D E SHAW RESEARCH   (United States)

^c Howard Hughes Medical Institute   (United States)

^d Mosaic Laboratories LLC   (United States)

^e Attenuon LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATN 658; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 77957797120     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10296     Document Type: Article

References (31)

1. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, and Li Y (2006). Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37, 1442-1451.
2. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, and Rao JS (1994). Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54, 5016-5020.
3. Hildenbrand R and Schaaf A (2009). The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 34, 15-23.
4. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, and Pfitzenmaier J (2009). Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int 104, 29-34.
5. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, and Shariat SF (2008). Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 55, 1124-1133.
6. Subramanian R, Gondi CS, Lakka SS, Jutla A, and Rao JS (2006). SiRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 28, 831-839.
7. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, and Rao JS (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280, 36529-36540.
8. Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, and Laug WE (2004). Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest 84, 667-678.
9. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, and Graeff H (1994). Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337, 131-134.
10. Ellis V, Behrendt N, and Danø K (1991). Plasminogen activation by receptorbound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266, 12752-12758.
11. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, and Terao T (1994). Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 57, 727-733.
12. Hu XW, Duan HF, Gao LH, Pan SY, Li YM, Xi Y, Zhao SR, Yin L, Li JF, Chen HP, et al. (2008). Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther 7, 651-659.
13. Tang CH, Hill ML, Brumwell AN, Chapman HA, and Wei Y (2008). Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with {beta}1 integrins. J Cell Sci 121, 3747-3756.
14. Zhang F, Tom CC, Kugler MC, Ching TT, Kreidberg JA, Wei Y, and Chapman HA (2003). Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell-cell contact. J Cell Biol 163, 177-188.
15. Okumura Y, Kamikubo Y, Curriden SA, Wang J, Kiwada T, Futaki S, Kitagawa K, and Loskutoff DJ (2002). Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 277, 9395-9404.
16. Margheri F, D'Alessio S, Serratí S, Pucci M, Annunziato F, Cosmi L, Liotta F, Angeli R, Angelucci A, Gravina GL, et al. (2005). Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12, 702-714.
17. Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZA, Lakka SS, Roth JA, Fang B, Sawaya R, et al. (1999). Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 59, 3369-3373.
18. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, et al. (2005). Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65, 7775-7781.
19. Bdeir K, Kuo A, Mazar A, Sachais BS, Xiao W, Gawlak S, Harris S, Higazi AA, and Cines DB (2000). A region in domain II of the urokinase receptor required for urokinase binding. J Biol Chem 275, 28532-28538.
20. Guo Y, Mazar AP, Lebrun JJ, and Rabbani SA (2002). An antiangiogenic urokinasederived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62, 4678-4684.
21. Yang M, Burton DW, Geller J, Hillegonds DJ, Hastings RH, Deftos LJ, and Hoffman RM (2006). The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clin Cancer Res 12, 2602-2606.
22. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, and Rabbani SA (2006). A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 9, 2271-2280.
23. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, and Stoppelli MP (1999). Urokinase receptor interacts with α(v)β5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59, 5307-5314.
24. D'Alessio S and Blasi F (2009). The urokinase receptor as an entertainer of signal transduction. Front Biosci 14, 4575-4787.
25. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, and Rao JS (2007). Downregulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 31, 19-27.
26. Van Buren G II, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, and Ellis LM (2009). Targeting the urokinase plasminogen activator receptor (uPAR) with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 115, 3360-3368.
27. Coleman RE (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12, 6243s-6249s.
28. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, and Huang M (2008). Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 15, 422-423.
29. Mazar AP, Ternansky RJ, Parry GC, Gladstone PL, and Gawlak S, Inventors. Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof. WO/2005/048822. June 2, 2005.
30. Alberti C (2008). Genetic and microenvironmental implications in prostate cancer progression and metastasis. Eur Rev Med Pharmacol Sci 12, 167-175.
31. Henić E, Borgfeldt C, Christensen IJ, Casslén B, and Høyer-Hansen G (2008). Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 14, 5785-5793.